AstraZeneca has partnered with BIND Therapeutics in a deal potentially worth US$199 M to use the company’s Medicinal Nanoengineering® platform to develop and commercialise an Accurin™, a targeted and programmable nanomedicine, based on a molecularly targeted kinase inhibitor developed by AstraZeneca. With the deal, the big pharma company becomes BIND’s third major Accurin collaborator. AstraZeneca has also entered into an agreement with Horizon Discovery to evaluate the company’s HD-001 kinase programme targeting K-Ras mutant tumours. The two deals follow the March 2013 announcement of a major restructuring of AstraZeneca’s R&D operations.